Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (61)

IV-01Nikolaos Alimpertis

Revising the assessment of bioequivalence in the light of finite absorption time (FAT) concept: The axitinib case

Thursday 15:00-16:30

IV-02Rami Ayoun Alsoud

Model-based Allometric Scaling Approaches for Predicting Human Pharmacokinetics of CB 4332, a Therapeutic Complement Factor I Protein

Thursday 15:00-16:30

IV-03Geraldine Celliere

A novel model-integrated design for bioequivalence of long acting injectables

Thursday 15:00-16:30

IV-04Vanessa Baier

PBPK model-guided assessment of a liver function test

Thursday 15:00-16:30

IV-05Pavel Balazki

PB-QSP model of type 2 diabetes for individualized prediction of treatment combination outcomes with metformin, DPP4i, and SGLT2i.

Thursday 15:00-16:30

IV-06Sara Bettonte

Cabotegravir pharmacokinetics after oral and intramuscular administration using physiologically based pharmacokinetic modelling

Thursday 15:00-16:30

IV-07Dominic Bräm

Opportunities of Covariate Data Imputation with Machine Learning for Pharmacometricians in R

Thursday 15:00-16:30

IV-08Katherine Briceno

Feedforward neural network as a surrogate for the reinforcement learning action-value function in a model-informed precision dosing oncology application

Thursday 15:00-16:30

IV-09Núria Buil Bruna

Can mAb dose selection in IBD be supported by public domain data from other immune-mediated inflammatory diseases?

Thursday 15:00-16:30

IV-10Letizia Carrara

Prospective predictions of drug pharmacokinetics and food effect in pediatrics via PBPK modelling

Thursday 15:00-16:30

IV-11Simon Carter

The development of artificial neural networks for the prediction of influential individuals and outlying individuals and their application during the model building process

Thursday 15:00-16:30

IV-12Estelle Chasseloup

Comparison of seven NLMEM approaches to test for drug effect using real placebo data

Thursday 15:00-16:30

IV-13Marylore Chenel

Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children

Thursday 15:00-16:30

IV-14Suein Choi

Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients

Thursday 15:00-16:30

IV-15Suein Choi

DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data

Thursday 15:00-16:30

IV-16Pavlos Chrysafidis

Re-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPK) models

Thursday 15:00-16:30

IV-17Yumi Cleary

Physiologically-based pharmacokinetic modelling of basmisanil to evaluate CYP3A mediated victim and perpetrator drug-drug interaction propensity

Thursday 15:00-16:30

IV-18Emmanuelle Comets

Conditional non-parametric bootstrap for non-linear mixed effect models

Thursday 15:00-16:30

IV-19Marina Cuquerella Gilabert

Towards PBPK model development for oral absorption in PhysPK

Thursday 15:00-16:30

IV-20Alessandro De Carlo

A Two-Stages Global Sensitivity Analysis in presence of correlated inputs: Application on a Tumor-in-host-growth Inhibition model based on the Dynamic Energy Budget theory

Thursday 15:00-16:30

IV-21Thibaud Derippe

Accelerating robust virtual patient (VP) population generation by substituting ODE solving with simple parameter comparisons

Thursday 15:00-16:30

IV-22Paul Matthias Diderichsen

Characterising the onset of response using public domain data and MBMA: application cases in Atopic Dermatitis and Psoriatic Arthritis

Thursday 15:00-16:30

IV-23Dominic Tong

Comparing full Bayesian estimation to maximum a posteriori (MAP) Bayesian estimation in three routine clinical care scenarios

Thursday 15:00-16:30

IV-24Julie Dudasova

Leveraging immunogenicity data and logistic regression for detection of covariate effects on vaccine efficacy

Thursday 15:00-16:30

IV-25Jeroen Elassaiss-Schaap

Mixing of variability in the log-domain with normal-domain variability components may lead to biased estimation

Thursday 15:00-16:30

IV-26Nivea M. F. Voelkner

Implementation of Estimation Step Refinements to Support Runtime Reduction for Model Building in NONMEM® 7

Thursday 15:00-16:30

IV-27Laura Fuhr

Peeling the grapefruit – investigating the drug interaction potential of grapefruit juice as CYP3A4 inhibitor using physiologically-based pharmacokinetic modeling

Thursday 15:00-16:30

IV-28Mohamed Gewily

Parametric and Non-Parametric Methods in Clinical Decision Making- A Comparison of Bias and Precision using Real Clinical Data

Thursday 15:00-16:30

IV-29Sungwoo Goo

Explainable covariate screening method using Artificial Neural Network (ANN) for Non-linear Mixed Effect Modeling

Thursday 15:00-16:30

IV-30Alzahra Hamdan

Automatic Development of Pharmacokinetic Structural Models – Pharmpy Model Search Tool

Thursday 15:00-16:30

IV-31Zhe Huang

Comparison of PK models using normal and log-transformed scale data

Thursday 15:00-16:30

IV-32Jasmine Hughes

PKPDposterior: R package for structured full-Bayesian model-informed precision dosing

Thursday 15:00-16:30

IV-33Itziar Irurzun Arana

A Long-Short Term Memory Approach to Predicting Neutrophil Count in Patients Undergoing Drug Treatment

Thursday 15:00-16:30

IV-34Martin Johnson

Developing a reinforcement learning algorithm to determine an optimal dosing regimen for cancer treatment

Thursday 15:00-16:30

IV-35Niclas Jonsson

Efficient and relevant stepwise covariate model building for pharmacometrics

Thursday 15:00-16:30

IV-36Christos Kaikousidis

Implementation of non-linear mixed effects models in NONMEM described by fractional differential equations.

Thursday 15:00-16:30

IV-37Wojciech Krzyzanski

Pharmacodynamic age structured population model for cell trafficking

Thursday 15:00-16:30

IV-38Chun Liu

Comparison of performances of the open-source R package “nlmixr” vs. Monolix for population pharmacokinetics of continuous infusion meropenem in patients with onco-hematological malignancies

Thursday 15:00-16:30

IV-39Helena Loer

Dose Adaptations for Drug-Gene and Drug-Drug Interactions involving Clopidogrel – A Physiologically based Pharmacokinetic (PBPK) Modeling Approach

Thursday 15:00-16:30

IV-40James Lu

Neural Ordinary Differential Equations for Tumor Dynamics Modeling and Overall Survival Predictions

Thursday 15:00-16:30

IV-41Julia Macente

Application of Physiologically-Based Pharmacokinetics using Simcyp to predict the exposure to Valproic Acid in human milk and pediatrics

Thursday 15:00-16:30

IV-42Fatima Zahra Marok

Physiologically-based pharmacokinetic modeling of drug-drug interactions with ketoconazole and its metabolite deacetyl-ketoconazole

Thursday 15:00-16:30

IV-43Uri Nahum

Innovative Machine Learning Based Algorithm to Differentiate Between Diabetes Insipidus and Primary Polydipsia in Clinical Practice

Thursday 15:00-16:30

IV-44Nina Nauwelaerts

Physiologically-Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to Sildenafil and Bosentan: a contribution from the ConcePTION Project

Thursday 15:00-16:30

IV-45Morgane PHILIPP

Model-based bioequivalence approach: robustness to model misspecification for sparse pharmacokinetic bioequivalence studies

Thursday 15:00-16:30

IV-46Fiona Plait

Physiologically Based Pharmacokinetic Modeling of a CYP3A4-Mediated Drug-Drug Interaction: Prediction of Victim of Induction, not Inhibition, with a Moderate Fraction Metabolized by CYP3A4

Thursday 15:00-16:30

IV-47Alicja Puszkiel

A minimal PBPK model for plasma and cerebrospinal fluid pharmacokinetics of trastuzumab in patients with leptomeningeal carcinomatosis

Thursday 15:00-16:30

IV-48Javier Reig-López

A Physiologically Based Pharmacokinetic Model for Open Acid and Lactone Forms of Atorvastatin and Its Two Metabolites

Thursday 15:00-16:30

IV-49Davide Ronchi

Facing the limits of the genetic algorithms for covariate selection

Thursday 15:00-16:30

IV-50Mark Sale

Comparison of Robustness and Efficiency of Four Machine Learning Algorithms for Identification of Optimal Population Pharmacokinetic Models

Thursday 15:00-16:30

IV-51Ayatallah Saleh

Elucidating the complex pharmacokinetics of voriconazole leveraging a middle-out approach

Thursday 15:00-16:30

IV-52Morwarid Shahhossini

Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock

Thursday 15:00-16:30

IV-53Yesong Shin

Population pharmacokinetic modelling for enterohepatic circulation of leflunomide in healthy Korean

Thursday 15:00-16:30

IV-54Florian Simon

Application of the Quantitative System Toxicology model of drug-induced liver injury DILIsym to evaluate the hepatotoxic potential of drugs in early development

Thursday 15:00-16:30

IV-55Erik Sjögren

A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework

Thursday 15:00-16:30

IV-56Victoria Smith

PKPDAI: Unlocking Pharmacokinetic Data from Tables with Natural Language Processing

Thursday 15:00-16:30

IV-57Victor Sokolov

Deciphering the mechanisms of drug effects on cardiovascular system through semi-mechanistic modeling of preclinical telemetry data: a validation study

Thursday 15:00-16:30

IV-58Britta Steffens

Assessment of sensitivity and specificity in the context of pharmacometrics-based decision support tools: application to hyperbilirubinemia in neonates

Thursday 15:00-16:30

IV-59Vo Thanh

Covariate Modelling and Bayesian Inference for Physiologically Based Pharmacokinetic Models

Thursday 15:00-16:30

IV-60Franziska Thoma

Simple and illustrative model to study Bayesian hierarchical modelling approaches for continued learning in model-informed precision dosing

Thursday 15:00-16:30

IV-61Eunsol Yang

Prediction of gastric pH-mediated drug exposure changes using physiologically based pharmacokinetic modeling: A case study of itraconazole

Thursday 15:00-16:30